All Updates

All Updates

icon
Filter
Funding
En Carta Diagnostics raises EUR 1.5 million in pre-seed funding to advance Lyme disease testing kits
Precision Medicine
May 27, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

May 27, 2024

En Carta Diagnostics raises EUR 1.5 million in pre-seed funding to advance Lyme disease testing kits

Funding

  • Point-of-care molecular diagnostics startup En Carta Diagnostics has raised EUR 1.5 million (USD 1.63 million) in a pre-seed funding round led by CentraleSupélec Venture, with participation from several other investors.

  • The raised funds will be channeled toward achieving preclinical data on a diagnostic kit prototype for chronic Lyme disease. The company also plans to use the funds to establish a robust ecosystem and enhance its market entry strategies.

  • Based in France, En Carta Diagnostics is a biotechnology company that develops point-of-care (POC) molecular diagnostics for various pathogens kits using synthetic biology. The company’s main therapeutic focus area is chronic Lyme disease. En Carta’s technology facilitates the creation of diagnostic kits that can be used without specialized equipment or training.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.